Polissacarídeo de Escherichia coli na Prevenção da Infeção do Trato Urinário Recorrente: Uma Revisão Baseada na Evidência

Manuel Tinoco; Mélody Santos; Conceição Reitor; Andreia Rodrigues; João Monteiro

doi:10.20344/amp.9367

Polysaccharide of Escherichia coli in the Prevention of Recurrent Urinary Tract Infection: An Evidence-Based Review

Authors

Manuel Tinoco Unidade Saúde Familiar Casa dos Pescadores. Póvoa de Varzim.
Mélody Santos Unidade Saúde Familiar Casa dos Pescadores. Póvoa de Varzim.
Conceição Reitor Unidade Saúde Familiar Casa dos Pescadores. Póvoa de Varzim.
Andreia Rodrigues Unidade Saúde Familiar Casa dos Pescadores. Póvoa de Varzim.
João Monteiro Unidade Saúde Familiar Casa dos Pescadores. Póvoa de Varzim.

DOI:

https://doi.org/10.20344/amp.9367

Keywords:

Adjuvants, Immunologic/therapeutic use, Escherichia coli Infections, Urinary Tract Infections, Uropathogenic Escherichia coli

Abstract

Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.
Material and Methods: We performed a systematic review in evidence-based medicine databases with rigorous bibliography selection.
Results: We found an effective decrease of recurrences in test groups.
Discussion: We recommend the administration of the vaccine as prophylaxis of recurrent cystitis.
Conclusion: The vaccine has impact on the recurrent cystitis relapse rate. We suggest that more studies be carried out to evaluate the vaccine cost-benefit and its effectiveness in complicated urinary infections.

Downloads

Download data is not yet available.

Downloads

PDF (Português)

Published

2018-03-29

How to Cite

Tinoco M, Santos M, Reitor C, Rodrigues A, Monteiro J. Polysaccharide of Escherichia coli in the Prevention of Recurrent Urinary Tract Infection: An Evidence-Based Review. Acta Med Port [Internet]. 2018 Mar. 29 [cited 2024 Nov. 23];31(3):165-9. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/9367

Download Citation

Issue

Vol. 31 No. 3 (2018): March

Section

Review Articles

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.